Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
- By: Patrick Dougherty, PhD, Senior Scientist, Entrada Therapeutics
- At: 2022 Boulder Peptide Symposium
- On: November 10, 2022
DownloadNovember 10, 2022 -
2022 Boulder Peptide Symposium
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 27th International Annual Congress of the World Muscle Society (WMS)
- On: October 14, 2022
DownloadOctober 14, 2022 -
Development of a Novel, EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: https://www.wms2022.com/page/home
- On: October 11, 2022
DownloadOctober 11, 2022 -
A Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Myotonic Dystrophy Type 1
- By: Xiulong Mark Shen, PhD, Senior Scientist, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 2, 2022
DownloadOctober 2, 2022 -
Development of a Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy
- By: Xiang Li, PhD, Associate Director, Discovery Research, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 2, 2022
DownloadOctober 2, 2022 -
Endosomal Escape Vehicle-Oligonucleotide Conjugates for the Targeted Upregulation and Downregulation of Gene Expression
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 2, 2022
DownloadOctober 2, 2022